Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Success Puts ThermoCool First In Line For AF Ablation Indication

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Biosense Webster's Navistar ThermoCool saline irrigated radio-frequency ablation catheterhas the inside track to become the first ablation catheter with an FDA-approved indication for atrial fibrillation following a unanimous recommendation from the agency's Circulatory System Devices Panel

You may also be interested in...



Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone

The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says

Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone

The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says

FDA Approves J&J’s Navistar ThermoCool For Atrial Fibrillation Ablation

With PMA approval Feb. 6, Johnson & Johnson/Biosense Webster's NaviStar ThermoCool and EZ Steer ThermoCool Navigational became the first cardiac ablation catheters approved by FDA specifically for treatment of atrial fibrillation

Related Content

UsernamePublicRestriction

Register

MT026819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel